Objective: We aimed to investigate the prognostic significance
of intraductal carcinoma in radical prostatectomy (RP) specimens and
predictive value of IDC-P for biochemical recurrence and adjuvant
therapy decision. Method: Patients who underwent RP between 2000-2014
with final pathological stage pT3a and negative surgical margins (Group
1, n=35) and pT2 with positive surgical margins (Group 2, n=32) were
included. RP specimens were re-evaluated for the presence of IDC-P
component and other prognostic factors. In both groups, prognostic
factors were compared according to the presence of IDC-P and biochemical
recurrence status. Results: In group 1, IDC-P was detected in 5 cases
and biochemical recurrence was detected in 3 cases. Patients with IDC-P
showed significantly higher biochemical recurrence than those without
IDC-P (p=0.002). In univariate analysis, IDC-P was found to be
significantly associated with worse progression free survival
(p<0.001). In group 2, IDC-P was detected in 4 cases and
biochemical recurrence was detected in 10 cases. Also, tumor volume was
significantly higher in patients with IDC-P than those without IDC-P
(p=0.02). IDC-P was also significantly associated with worse progression
free survival in group 2 (p=0.033). Conclusions: In both groups, IDC-P
is a prognostic factor for progression free survival and / or
biochemical recurrence. Especially in these patients, presence of IDC-P
might be helpful for postoperative adjuvant therapy management decision.
Keywords: radical prostatectomy, intraductal carcinoma of prostate
(IDC-P), prostate cancer, biochemical recurrence, progression free
survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.